KR102824611B1 - Lma-발현 암 및 자가면역 장애를 치료하기 위한 항-람다 골수종 항원(lma) 결합 단백질 - Google Patents

Lma-발현 암 및 자가면역 장애를 치료하기 위한 항-람다 골수종 항원(lma) 결합 단백질 Download PDF

Info

Publication number
KR102824611B1
KR102824611B1 KR1020207027033A KR20207027033A KR102824611B1 KR 102824611 B1 KR102824611 B1 KR 102824611B1 KR 1020207027033 A KR1020207027033 A KR 1020207027033A KR 20207027033 A KR20207027033 A KR 20207027033A KR 102824611 B1 KR102824611 B1 KR 102824611B1
Authority
KR
South Korea
Prior art keywords
seq
ser
binding protein
lma
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207027033A
Other languages
English (en)
Korean (ko)
Other versions
KR20210005553A (ko
Inventor
로잔 던
Original Assignee
해마로직스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900534A external-priority patent/AU2018900534A0/en
Application filed by 해마로직스 리미티드 filed Critical 해마로직스 리미티드
Publication of KR20210005553A publication Critical patent/KR20210005553A/ko
Application granted granted Critical
Publication of KR102824611B1 publication Critical patent/KR102824611B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207027033A 2018-02-20 2019-02-20 Lma-발현 암 및 자가면역 장애를 치료하기 위한 항-람다 골수종 항원(lma) 결합 단백질 Active KR102824611B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018900534A AU2018900534A0 (en) 2018-02-20 Composition and method
AU2018900534 2018-02-20
PCT/AU2019/050137 WO2019161443A1 (en) 2018-02-20 2019-02-20 Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders

Publications (2)

Publication Number Publication Date
KR20210005553A KR20210005553A (ko) 2021-01-14
KR102824611B1 true KR102824611B1 (ko) 2025-06-24

Family

ID=67686653

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207027033A Active KR102824611B1 (ko) 2018-02-20 2019-02-20 Lma-발현 암 및 자가면역 장애를 치료하기 위한 항-람다 골수종 항원(lma) 결합 단백질

Country Status (10)

Country Link
US (2) US11447571B2 (https=)
EP (1) EP3755724A4 (https=)
JP (2) JP7490559B2 (https=)
KR (1) KR102824611B1 (https=)
CN (1) CN111918879B (https=)
AU (2) AU2019225446B2 (https=)
BR (1) BR112020017018A2 (https=)
CA (1) CA3091711A1 (https=)
SG (1) SG11202007925SA (https=)
WO (1) WO2019161443A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250326864A1 (en) * 2022-06-13 2025-10-23 Paradox Immunotherapeutics Inc. Monoclonal antibodies targeting conformation-specific epitopes of immunoglobulin light chains of the lambda subclass
WO2025236034A1 (en) * 2024-05-13 2025-11-20 HaemaLogiX Ltd Anti-lma binding proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082409A1 (en) * 2004-02-27 2005-09-09 Pacmab Limited Target for b-cell disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100187181A1 (en) * 2009-01-29 2010-07-29 Sortwell Edwin T Method for Dispersing and Aggregating Components of Mineral Slurries
WO2010115238A1 (en) * 2009-04-07 2010-10-14 Immune System Therapeutics Ltd Method for treating immune disorders
GB201203938D0 (en) * 2012-03-06 2012-04-18 Binding Site Group The Ltd Assay system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082409A1 (en) * 2004-02-27 2005-09-09 Pacmab Limited Target for b-cell disorders

Also Published As

Publication number Publication date
CA3091711A1 (en) 2019-08-29
EP3755724A1 (en) 2020-12-30
JP2021514369A (ja) 2021-06-10
CN111918879A (zh) 2020-11-10
US20230174675A1 (en) 2023-06-08
JP2024100838A (ja) 2024-07-26
CN111918879B (zh) 2024-10-15
JP7798956B2 (ja) 2026-01-14
SG11202007925SA (en) 2020-09-29
US12435158B2 (en) 2025-10-07
US20210230309A1 (en) 2021-07-29
WO2019161443A1 (en) 2019-08-29
EP3755724A4 (en) 2022-03-23
BR112020017018A2 (pt) 2020-12-29
AU2021202092A1 (en) 2021-04-29
AU2019225446A1 (en) 2020-10-08
US11447571B2 (en) 2022-09-20
KR20210005553A (ko) 2021-01-14
JP7490559B2 (ja) 2024-05-27
AU2019225446B2 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
KR102940310B1 (ko) 항-nkg2a 항체 및 그의 용도
CN111094352B (zh) B7-h4抗体及其使用方法
CA2501653C (en) Human anti-ifn-.gamma. neutralizing antibodies as selective ifn-.gamma. pathway inhibitors
CA2501984C (en) Erythropoietin receptor binding antibodies
CN107531783B (zh) 靶向bmp6抗体的组合物和方法
KR102904286B1 (ko) 세포 부착 분자3에 결합하는 항체
US20040175379A1 (en) Erythropoietin receptor binding antibodies
CN115151570B (zh) 抗人cd19抗体
KR102933484B1 (ko) 항-il-27 항체 및 그의 용도
KR20170065029A (ko) 증강된 면역 반응 및 암 요법을 위한 조성물 및 사용 방법
CN108650886A (zh) 多价和多特异性gitr-结合融合蛋白
CN110799538B (zh) 抗cd3抗体及其制备和使用方法
KR20220062500A (ko) 항-cd39 항체 조성물 및 방법
CN106795223B (zh) 针对Fcγ受体IIB及Fcε受体的抗体
KR102879521B1 (ko) 항-il-27 항체 및 이의 용도
KR20140059168A (ko) 시신경 척수염 치료용 조성물 및 치료 방법
WO2012172495A1 (en) Compositions and methods for antibodies targeting tem8
KR20200044899A (ko) 암의 치료 및 진단을 위한 tim-3 길항제
AU2019348815B2 (en) Antagonists
CN114685660A (zh) 抗cldn18.2抗体及其制备方法和应用
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
KR102824611B1 (ko) Lma-발현 암 및 자가면역 장애를 치료하기 위한 항-람다 골수종 항원(lma) 결합 단백질
CN101918549B (zh) 改良的人源化的抗-人α9-整联蛋白抗体
AU2019210504B2 (en) Human antigen binding proteins that bind beta-Klotho, FGF receptors and complexes thereof
CN117203241A (zh) 抗Siglec15抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200918

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220217

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240823

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250402

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250619

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250620

End annual number: 3

Start annual number: 1

PG1601 Publication of registration